Recall due to presence of chloroform
Therapeutic Goods Administration (TGA)
Australian Government Department of Health
Main menu
- Home
- Safety information
- Consumers
- Health professionals
- Report a problem or side effect
- Accessing unapproved products
- Advertising
- Medicines
- Medical devices
- Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL)
- Breast implant hub
- Changes to labelling and regulation of hard surface disinfectants (commencing 1 April 2019)
- Information for medical practitioners on pending up-classification of surgical mesh devices
- Importing & supplying medical devices
- Advice about medical devices for health professionals
- Biologicals
- Safety information
- Other resources
- Health professional information & education
- Industry
- SME Assist
- When to engage with the TGA
- Basics of therapeutic goods regulation
- Meeting your obligations workshops
- Educational videos
- Overview of applying for market authorisation
- Understanding ingredient requirements
- Overview of medical devices and IVD regulation
- Researcher considerations
- Interactive decision tools
- Useful resources for business and researchers
- Regulation basics
- How therapeutic goods are regulated in Australia
- Australian Register of Therapeutic Goods
- Industry educational materials
- Legislation & legislative instruments
- Advertising hub
- Labelling & packaging
- Ingredients in therapeutic goods
- Exporting therapeutic goods
- Importing therapeutic goods
- Clinical trials
- Cosmetics
- International scientific guidelines
- Safety information for industry
- Medicine shortages
- Advertising therapeutic goods
- Prescription medicines
- Over-the-counter medicines
- Complementary medicines
- Sunscreens
- Medical devices & IVDs
- Biologicals
- Blood and blood components
- Other therapeutic goods
- Manufacturing therapeutic goods
- Scheduling of medicines & poisons
- SME Assist
- About the TGA
- News room
